Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ABCL
AbCellera Biologics Inc. Common Shares
stock NASDAQ

Market Open
Jul 28, 2026 12:03:44 PM EDT
5.20USD-0.952%(-0.05)2,648,621
5.20Bid   5.21Ask   0.01Spread
Pre-market
Jul 27, 2026 9:29:30 AM EDT
5.41USD+1.883%(+0.10)0
After-hours
Jul 27, 2026 4:51:30 PM EDT
5.35USD+2.099%(+0.11)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 9, 2022
05:00PM EST  AbCellera and Its Collaborators Released New Preclinical Data Confirming That the Investigational Antibody Bebtelovimab Maintains Both Full and Potent Neutralization Activity Against the Omicron Variant and All Other Known SARS-COV-2 Variants of Concern   Benzinga
Dec 21, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021   Benzinga
06:16AM EST  Benchmark Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $27   Benzinga
Dec 6, 2021
08:03AM EST  Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns   Benzinga
Dec 3, 2021
04:05PM EST  AbCellera Reports Balanivimab, Estesevimab Authorized As Antibody Therapy For Emergency Use In COVID-19 Patients Under Age 12   Benzinga
Dec 2, 2021
09:12AM EST  AbCellera Announces Appointment Of Neil Aubuchon As CCO   Benzinga
Nov 19, 2021
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
04:50AM EST  Piper Sandler Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $33   Benzinga
Nov 9, 2021
06:07PM EST  AbCellera Biologics Q3 EPS $(0.08) Down From $(0.02) YoY, Sales $5.51M Down From $9.36M YoY   Benzinga
06:07PM EST  AbCellera Biologics Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $9.36M Up From $5.51M YoY   Benzinga
12:08PM EST  How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
Nov 2, 2021
04:25PM EDT  AbCellera Highlights Additional Purchase By US Government From Eli Lilly For 614,000 Additional Doses Of AbCellera-Discovered Bamlanivimab With Etesevimab   Benzinga
Sep 23, 2021
09:59AM EDT  AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies   Benzinga
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
06:49AM EDT  Cramer's Advice On Ulta Beauty, Laredo Petroleum And More   Benzinga
Sep 22, 2021
06:02PM EDT  AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies; No Terms Disclosed   Benzinga
Sep 21, 2021
01:57PM EDT  Lilly To Supply EU, EEA With Up To 220,000 Doses Of AbCellera-Discovered Bamlanivimab Together With Etesevimab For Treatment Of Confirmed COVID-19   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
05:31AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.10 A.M. EDT).   RTTNews
Sep 16, 2021
04:16PM EDT  AbCellera Biologics Reports FDA Emergency Use Authorization for Its Bamlanivimab, Etesevimab Administered Together Expanded To Include Post-Exposure Prophylaxis For COVID-19; Same News As Eli Lilly Earlier   Benzinga
Sep 15, 2021
10:36AM EDT  Shares of AbCellera Biologics Inc. (ABCL) are gaining over 5% on Wednesday morning after the company announced that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage its AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.   RTTNews
09:05AM EDT  AbCellera Announces Collaboration With Moderna To 'Discover Therapeutic Antibodies for mRNA Medicines'   Benzinga
Sep 13, 2021
09:06AM EDT  AbCellera Acquires TetraGenetics; Terms Not Disclosed   Benzinga
Aug 13, 2021
07:45AM EDT  Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $49   Benzinga
Aug 12, 2021
05:00PM EDT  AbCellera Biologics Q2 EPS $(0.01) Misses $0.11 Estimate   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
07:42AM EDT  EQRx And AbCellera Announce Collaboration To 'Accelerate the Advancement of New Innovative Medicines'; Financial Terms Not Disclosed   Benzinga
07:00AM EDT  EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines   Business Wire
Aug 3, 2021
06:14AM EDT  Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF- Superfamily Member for the Treatment of Cancer   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 21, 2021
07:52AM EDT  The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 22, 2021
09:12AM EDT  AbCellera Says Continues Expansion And Strengthens Future Pandemic Preparedness With First-Of-Its-Kind GMP Manufacturing Facility For Therapeutic Antibodies In Canada   Benzinga
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
Jun 10, 2021
05:11PM EDT  AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares   Business Wire
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
May 14, 2021
10:13AM EDT  Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $51   Benzinga
May 13, 2021
04:49PM EDT  AbCellera Biologics Q1 EPS $0.37 Misses $0.38 Estimate, Sales $203.00M Beat $196.48M Estimate   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 6, 2021
09:16AM EDT  AbCellera Partners And Angios To Develop Therapeutics To Combat Blindness Caused By Diabetic Retinopathy   Benzinga
May 4, 2021
09:31AM EDT  AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials   Benzinga
06:51AM EDT  AbCellera Announces Second Antibody From Its Collaboration With Eli Lilly Has Entered Clinical Trials In Patients With Mild-To-Moderate COVID-19   Benzinga
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 14, 2021
04:08PM EDT  AbCellera Reports Strategic Multi-Target Antibody Discovery Collab With Empirico   Benzinga
Apr 5, 2021
02:01PM EDT  AbCellera Biologics Says Peer-Reviewed Data 'Demonstrate Bamlanivimab's High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19'   Benzinga
06:59AM EDT  Invitae Shares Are Trading Higher On SoftBank's Potential $1.2B Debt Investment: WSJ   Benzinga
Apr 1, 2021
10:05AM EDT  AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration   Benzinga
09:37AM EDT  AbCellera Reports New Multi-Year, Multi-Target Antibody Discovery Collaboration With Gilead   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
07:17AM EDT  Stifel Maintains Buy on AbCellera Biologics, Lowers Price Target to $55   Benzinga
Mar 29, 2021
04:15PM EDT  AbCellera FY20 EPS $0.45, Up From $(0.01) YoY, Sales $233M, 1,908% YoY   Benzinga
04:16AM EDT  Earnings Scheduled For March 29, 2021   Benzinga
Mar 8, 2021
11:42AM EST  AbCellera Biologics shares were trading higher after the European Medicine Agency advised use of the company's Bamlanivimab to treat COVID-19 patients.   Benzinga
Mar 5, 2021
03:32PM EST  AbCellera Reports European Medicines Agency Advised Use Of Co.-Discovered Bamlanivimab To Treat Confirmed COVID-19 Patients   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 8, 2021
05:05AM EST  SVB Leerink Maintains Outperform on AbCellera Biologics, Raises Price Target to $52   Benzinga
Jan 27, 2021
07:23AM EST  AbCellera Highlights Its Discovered Antibody, Bamlanivimab, To Be Developed With VIR-7831 For The Treatment Of COVID-19   Benzinga
Jan 26, 2021
07:16AM EST  AbCellera Highlights Results Of Lilly Trials Of Bamlanivimab, Notes Bamlanivimab Was Discovered By AbCellera   Benzinga
Jan 21, 2021
08:29AM EST  AbCellera Says Discovered Antibody Prevented COVID-19 In Nursing Homes, Reduced Risks By Up To 80% For Residents   Benzinga
Jan 19, 2021
04:44PM EST  AbCellera Biologics Granted U.S. Patent Covering Its Trianni Mouse Technology   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 5, 2021
10:42AM EST  AbCellera Biologics shares were trading higher after multiple firms initiated coverage on the stock with a bullish rating.   Benzinga
10:11AM EST  Benzinga's Top Upgrades, Downgrades For January 5, 2021   Benzinga
10:11AM EST  Berenberg Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $53   Benzinga
09:30AM EST  2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven   PR Newswire
07:30AM EST  SVB Leerink Initiates Coverage On AbCellera Biologics with Outperform Rating, Announces Price Target of $45   Benzinga
07:29AM EST  Credit Suisse Initiates Coverage On AbCellera Biologics with Outperform Rating   Benzinga
06:03AM EST  Stifel Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $59   Benzinga
05:11AM EST  BMO Capital Initiates Coverage On AbCellera Biologics with Outperform Rating, Announces Price Target of $48   Benzinga
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
11:23AM EST  AbCellera Biologics shares were trading higher after the company's 13D showed Peter Thiel reported a 5.3% stake in AbCellera as of December 15th.   Benzinga
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 28, 2020
04:54PM EST  Abcellera Biologics 13D Showed Peter Thiel Reports Had A Stake 5.3% In Co. As Of December 15   Benzinga
Dec 21, 2020
09:09AM EST  AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico   Benzinga
Dec 17, 2020
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 11, 2020
09:46AM EST  IPOs for today: VVOS, ABCL, EDTXU, GLAQU, TVACU, SNRHU, NBTX, ROCCU, GHVIU, CERT, FDMT, MOTVU, DWINU, CBAHU, PCPCU   Benzinga
09:27AM EST  AbCellera Biologics Inc. Shares Will Open For Quote At 10:35 a.m. EST, Expected To Open For Trade After 10:45 a.m. EST; IPO Priced At $20/Share   Benzinga
12:47AM EST  AbCellera Biologics is scheduled to make its debut on the Nasdaq Global Select Market today (December 11), under the ticker symbol "ABCL."   RTTNews
Dec 10, 2020
08:41AM EST  AbCellera Biologics Amended S-1 Shows Expectation For 23M Share IPO In $17-$18/Share Range; Co. To List On Nasdaq Under Symbol 'ABCL'   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC